U.S. stock futures were lower this morning, with the Dow futures falling around 400 points on Thursday.

Shares of Alto Neuroscience Inc (NYSE:ANRO) fell sharply in pre-market trading after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.

Alto Neuroscience shares dipped 13.6% to $20.16 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Akso Health Group – ADR (NASDAQ:AHG) fell 9.4% to $2.10 in pre-market trading.
• SharonAI Holdings Inc (NASDAQ:SHAZ) fell 8.8% to $25.19 in pre-market trading. SharonAI Holdings shares jumped around 22% on Wednesday after the company announced the signing of a five-year TCV AI infrastructure agreement with ESDS Software Solutions.
• Progress Software Corp (NASDAQ:PRGS) fell 8.3% to $23.00 in pre-market trading.
• Immunovant Inc (NASDAQ:IMVT) fell 8.3% to $23.02 in pre-market trading as the company announced Phase 3 study results for Batoclimab in Thyroid Eye Disease (TED).
• Americas Gold and Silver Corporation (NYSE:USAS) fell 8.1% to $5.14 in pre-market trading after gaining 7% on Wednesday.
• TRX Gold Corp (NYSE:TRX) fell 7.2% to $1.42 in pre-market trading.
• Rezolve AI PLC (NASDAQ:RZLV) fell 7% to $2.91 in pre-market trading after jumping 22% on Wednesday.
• Avino Silver & Gold Mines Ltd (NYSE:ASM) fell 6% to $6.20 in pre-market trading after gaining 4% on Wednesday.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.